Across TCGA pan-cancer cohorts, SPAG11A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPAG11A data layer compared with 16 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SPAG11A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPAG11A expression acts as an unfavorable survival marker.
KIRP, HNSC, and BRCA are the cancer types where SPAG11A Mutation most reproducibly stratifies survival.